China's Jiangsu Province Food and Drug Inspection Administration held a meeting on the research status of the COVID-19 treatment drug SIM0417.
According to the statement, SIM0417 is an oral drug for the treatment of 3CL targeted COVID-19 jointly developed by Simcere company, the Shanghai Institute of the Chinese Academy of Sciences and the Wuhan Institute of Virology. SIM0417 had received clinical approval from the Chinese State Food and Drug Inspection Administration on March 28, 2022.
On December 16, 208 patients participated in phase III clinical trials. The fastest release of the drug is expected in February 2023.
Be the first to comment